BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression - ScienceDirect
JCI - Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1
JQ1 reduces proliferation and survival of glioblastoma stem cells and... | Download Scientific Diagram
BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc | Cell Death & Disease
Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer | Scientific Reports
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases - Kulikowski - 2021 - Medicinal Research Reviews - Wiley Online Library
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer | Nature
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy | Future Science OA
Achieving clinical success with BET inhibitors as anti-cancer agents | British Journal of Cancer
BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer | bioRxiv
Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections | PNAS
Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer - ScienceDirect
Cancers | Free Full-Text | The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer | HTML
The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice | Translational Psychiatry
Frontiers | Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation - ScienceDirect
BET inhibitors: a novel epigenetic approach - Annals of Oncology
Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition | Science Translational Medicine
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors - eBioMedicine
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours | British Journal of Cancer
Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer - ScienceDirect
Bromodomain inhibitors in clinical trials | Download Table
